Skip to main content
Premium Trial:

Request an Annual Quote

Gentel to Collaborate with SCOPE Consortium

NEW YORK (GenomeWeb News) – Gentel Biosciences will collaborate with an international consortium focused on developing biomarkers for pregnancy complications, the company said.

The Screening for Pregnancy Endpoints (SCOPE) Study is establishing a pregnancy biobank that will be used to research tests that can predict major diseases of late-stage pregnancy, which affect 19 percent of worldwide pregnancies, the company said.

"Our goal is to develop a high performance screening test for preeclampsia" using Gentel's Apix Array platform, SCOPE Project Leader and University of Adelaide Professor Robyn North said in a statement.

Madison, Wis.-based GenTel will develop and validate a quantitative multiplex immunoassay using its microarray technologies to measure a large panel of analytes.

Financial terms of the agreement were not released.